Treatment of toxic liver damage by antihepatocytotoxic serum.
Acute liver failure (ALF) is a broad term that refers to both fulminant hepatic failure (FHF) and subfulminant hepatic failure (or late-onset hepatic failure). The latter term is reserved for patients with liver disease for up to 26 weeks prior to the development of hepatic encephalopathy. Some patients with previously unrecognized chronic liver disease decompensate and present with liver failure; although this technically is not FHF, discerning this at the time of presentation may not be possible (eg, Wilson disease). The objective of present research was to define suitable method for the treatment of toxic damage of the liver. We consider that liver changes occurred in the case of toxic damage can be reversed by administration of antihepatocytotoxic serum which has been developed by us. For this purpose we are going to induce liver toxic damage in the Wister line and investigate the liver regeneration cellular mechanisms after administration of antihepatocytotoxic serum. Experimental investigations were performed on Wister line male rats, animals were divided into four equal groups. In I and II groups we were modelling acute liver failure by injections of hepatotoxic agent CCL4 (I) and performing 70% hepatectomy (II), III group was served as control group, and IV group served as donors for HPCs. The main aspect of our study was to stimulate liver reparative regeneration and by this help to organ function restoration. Performed studies have shown hypertrophy and moderate hyperplasia of hepatocyte organelles. Oval shaped HPCs were also observed, Performed investigations had shown effectiveness of our ALF treatment method in terms of damaged liver function restoration, normalization of morphological picture and biochemical measurements and we hope that administration of antihepatocytotoxic serum developed by us can give a chance to patients with acute liver failure.
Topuria
D
D
Department of Anesthesiology, Georgian State Medical Academy.
Didava
G
G
Lobdjanidze
N
N
Sujashvili
L
L
D000818:Animals; D016913:Blood Component Transfusion / Q000379:methods*; D002251:Carbon Tetrachloride / Q000633:toxicity; D017114:Liver Failure, Acute / Q000097:blood* / Q000473:pathology / Q000628:therapy*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D044967:Serum
D002251:Carbon Tetrachloride